Русский
Prevalence of hepatitis B and C markers among the apparently healthy population of the Kaliningrad Region
DOI: https://dx.doi.org/10.18565/epidem.2020.10.4.13-20
Kyuregyan К.К., Isaeva О.V., Kichatova V.S., Karlsen А.А., Lopatukhina М.А., Potemkin I.А., Asadi Mobarhan F.A., Malinnikova Е.Yu., Krasnova O.G., Ivanov I.B., Rukosueva E.V., Znoyko O.O., Yushchuk N.D., Mikhailov М.I.
1) Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Moscow, Russia; 2) I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; 3) Infectious Diseases Hospital of the Kaliningrad Region, Kaliningrad, Russia; 4) A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia
Subjects and methods. A total of 1051 serum samples from the apparently healthy individuals of the Kaliningrad Region were examined. The investigation included people of 9 age groups: less than 1 year, 1–9, 10–14, 15–19, 20–29, 30–39, 40–49, 50–59, and more than 60 years old. Serological markers for HBV and HCV were identified using ELISA. HCV RNA and virus genotype were determined in the anti-HCV positive samples.
Results. The detection rate of HBsAg averaged 0.4% (95% CI: 0.11–1.01%) and that of anti-HBs was 17.1% (95% CI: 14.97–19.53%). No HBV and HCV co-infection cases were identified. The detection rate of anti-HCV averaged 2.9% (95% CI: 2.07–4.17%), the prevalence of current HCV infection confirmed by viral RNA detection was 1.8% (95% CI: 1.14–2.82%). The proportion of individuals with current infection among those positive for anti-HCV was 61.3%. The prevalence of current HCV infection in the adult population (aged 20 to 50 years) оf the Kaliningrad Region was 3.1% (95% CI: 1.9–5.0%), which was significantly higher than that in the children and adolescents aged less than 19 years (p < 0.05). The most common HCV genotypes were 1a (21%), 1b (37%), and 3a (32%).
Conclusion. The Kaliningrad Region is characterized by a high prevalence of HCV infection in the general population with relatively rare cases of HBV infection. The individuals over 19 years of age are at increased risk for HCV infection and should be included in screening programs. The region shows a high HCV genotypic diversity; genotypes 1a, 1b, and 3a are most common. This distinguishes to a large extent the Kaliningrad Region from all other Russian regions, where genotype 1a is rare.
Literature
1. Klushkina V.V., Kyuregyan K.K., Kozhanova T.V., Popova O.E., Dubrovina P.G., Isaeva O. V. Impact of universal hepatitis B vaccination on prevalence, infection-associated morbidity and mortality, and circulation of immune escape variants in Russia. PLoS One 2016; 11(6), e0157161. doi: 10.1371/journal.pone.0157161 2. Global health sector strategy on viral hepatitis 2016–021. Geneva: WHO, 2016. http://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng. pdf?ua=1 3. Численность населения Российской Федерации по муниципальным образованиям на 1 января 2019 года. http://www.gks.ru/free_doc/doc_ 2019/bul_dr/mun_obr2019.rar [Population of the Russian Federation by municipality as of January 1, 2019]. (In Russ.). http://www.gks.ru/free_doc/doc_2019/bul_dr/mun_obr 2019.rar 4. WHO guidelines on hepatitis B and C testing. Geneva: WHO, 2017. Licence: CC BY-NC-SA 3.0 IGO 5. Bian J., Schreiner A.D. Population-based screening of hepatitis C virus in the United States. Current Opinion in Gastroenterology 2019; 35(3): 177–82. doi:10.1097/MOG.0000000000000520 6. Кюрегян К.К., Соболева Н.В., Карлсен А.А., Кичатова В.С., Потемкин И.А., Исаева О.В. и др. Динамические изменения распространенности вируса гепатита С среди населения Республики Саха (Якутия) за последние 10 лет. Инфекционные болезни: новости, мнения, обучение 2019; 8(2): 16–26. doi: 10.24411/2305-3496-2019-12002 Kyuregyan K.K., Soboleva N.V., Karlsen A.A., Kichatova V.S., Potemkin I.A. et al. [Dynamic changes in the prevalence of hepatitis C virus in the general population in the republic of Sakha (Yakutia) over the last 10 years]. Infekcionnye bolezni: novosti, mneniya, obuchenie 2019; 8(2): 16–26. doi: 10.24411/2305-3496-2019-12002 (In Russ.). 7. Kyuregyan K.K., Malinnikova E.Y., Soboleva N.V., Isaeva O.V., Karlsen А.А. et al. Community screening for hepatitis C virus infection in a low-prevalence population. BMC Public Health 2019; 19(1): 1038. doi:10.1186/ s12889-019-7388-7 8. Kartashev V., Döring M., Nieto L., Coletta E., Kaiser R., et al. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J. Clin. Virol. 2016; 81, 82–9. doi: 10.1016/j.jcv.2016.05.010 9. McMahon B.J. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49(S5): S45–S55. https://doi.org/10.1002/hep.22898 10. Ganem D., Prince A.M. Hepatitis B virus infection – natural history and clinical consequences. New Engl. J. Med. 2004; 350(11): 1118–29. doi: 10.1056/NEJMra031087 11. Семенов А.В., Останкова Ю.В. Распространенность оккультного вирусного гепатита В среди доноров крови. Вестник гематологии 2018; 14(4): 45–6. Semenov A.V., Ostankova Yu.V. [Prevalence of occult viral hepatitis B among blood donors]. Vestnik gematologii 2018; 14(4): 45–6. (In Russ.).
About the Autors
Prof. Karen K. Kyuregyan, BD, Head, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: karen-kyuregyan@yandex.ru; ORCID: http://orcid.org/0000-0002-3599-117X
Olga V. Isaeva, Cand. Biol. Sci., Leading Researcher, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: isaeva.06@mail.ru; ORCID: https://orcid.org/0000-0002-2656-3667
Vera S. Kichatova, Researcher, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: vera_kichatova@mail.ru; ORCID: http://orcid.org/0000-0002-7838-6965
Anastasia A. Karlsen, Researcher, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: karlsen12@ gmail.com; ORCID: http://orcid.org/0000-0002-6013-7768
Maria A. Lopatukhina, Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: m.lopatukhina@gmail.com; https://orcid.org/0000-0001-6853-4154
Ilya A. Potemkin, Researcher, Department of Viral Hepatitis, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: axi0ma@mail.ru; ORCID: https://orcid.org/0000-0001-7559-4219
Fedor A. Asadi Mobarhan, Researcher, Laboratory of Viral Hepatitis, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia;I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: 1amfa@bk.ru
Elena Yu. Malinnikova, MD, Head, Department of Virology, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Leading Researcher, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: malinacgb@mail.ru; ORCID: https://orcid.org/0000-0002-5501-5707
Olga G. Krasnova, Head Physician. Infectious Diseases Hospital of the Kaliningrad Region, Kaliningrad, Russia; e-mail: inf-bol@infomed39.ru; ORCID: https://orcid.org/0000-0002-4404-4086
Igor B. Ivanov, Deputy Head Physician. Infectious Diseases Hospital of the Kaliningrad Region; Principal Nonstaff Infectiologist, Ministry of Health of the Kaliningrad Region, Kaliningrad, Russia; e-mail: inf-bol@infomed39.ru; ORCID: https://orcid.org/0000-0002-1875-8392
Elena V. Rukosueva, Head, Hepatology Room, AIDS Center, Infectious Diseases Hospital of the Kaliningrad Region, Kaliningrad, Russia; e-mail: rukosueva75@list.ru; ORCID:https://orcid.org/0000-0003-2550-8874
Olga O. Znoyko, MD, Associate Professor, Department of Infectious Diseases and Epidemiology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia; e-mail: olgaznoyko@yandex.ru; ORCID: https://orcid.org/0000-0002-4965-596X
Prof. Nikolaу D. Yushchuk, Academician of the Russian Academy of Sciences, Head, Department of Infectious Diseases and Epidemiology; President, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia; e-mail:prof.uyshuk@gmail.com; ORCID: https://orcid.org/0000-0003-1928-4747
Prof. Mikhail I. Mikhailov, Corresponding Member of the Russian Academy, MD, Research Adviser, Research Institute of Molecular and Personalized Medicine, Russian Medical Academy of Continuing Professional Education; Ministry of Health of Russia; Head, Laboratory of Viral Hepatitis, I.I. Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia; e-mail: michmich2@yandex.ru; ORCID: https://orcid.org/0000-0002-6636-6801
Similar Articles
